Evidence map›Paper›PMID 35379656›Full record

ArticleCold Spring Harbor perspectives in medicine2022

Human Endothelial Colony-Forming Cells.

Juan M Melero-Martin

Abstract read
In one paragraph

Article in Cold Spring Harbor perspectives in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Direct in vivo reprogramming to relieve tissue ischemia via induced vasculogenesis.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  9. Journal of xenobiotics · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. DMP1-mediated transformation of DPSCs to CD31Frontiers in cell and developmental biology · 2025
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Juan M Melero-MartinDepartment of Cardiac Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.ORCID 0000-0002-4689-8149

Funding

Vascular networks genetically engineered for protein drug deliveryR01HL128452 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI MELERO-MARTIN, JUAN M, WANG, BO · 2015 to 2024
$4.8M
Enhancing endothelial cell engraftment via transplantation of exogenous mitochondriaR01HL152133 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI Juan M Melero-Martin · 2021 to 2026
$3.1M
Regulation of endothelial cell specificationR01HL151450 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI MELERO-MARTIN, JUAN M, PU, WILLIAM TSWENCHING · 2021 to 2024
$2.5M
NHLBI NIH HHS R01 HL128452NHLBI NIH HHS R01 HL151450NHLBI NIH HHS R01 HL152133
6 · The paper itself

Abstract

Endothelial colony-forming cells (ECFCs) are progenitor cells that can give rise to colonies of highly proliferative vascular endothelial cells (ECs) with clonal expansion and in vivo blood vessel-forming potential. More than two decades ago, the identification of ECFCs in human peripheral blood created tremendous opportunities as having a clinically accessible source of autologous ECs could facilitate meaningful therapies with the potential to impact multiple vascular diseases. Nevertheless, until recently, the field of endothelial progenitor cells has been plagued with ambiguities and controversies, and reaching a consensus on the definition of ECFCs has not been straightforward. Moreover, although the basic phenotypical and functional characteristics of cultured ECFCs are now well established, some fundamental questions such as the origin of ECFCs and their physiological roles in health and disease remain incompletely understood. Here, I highlight some critical studies that have shaped our current understanding of ECFCs in humans. Insights into the biological attributes of ECFCs are essential for facilitating the clinical translation of their therapeutic potential.

Indexed as

Endothelial Progenitor CellsCells, CulturedHumansNeovascularization, PhysiologicStem Cells

Identifiers

PMID35379656
PMCPMC9530069

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.